Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide

BACKGROUND: Prostate cancer that recurs after initial treatment inevitably progresses to castration‐resistant prostate cancer (CRPC), the lethal stage of the disease. Despite improvements in outcomes from next generation androgen receptor (AR)‐axis inhibitors, CRPC remains incurable. Therapeutic str...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilling, Amanda B., Hwang, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617752/
https://www.ncbi.nlm.nih.gov/pubmed/31228231
http://dx.doi.org/10.1002/pros.23843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617752/
https://www.ncbi.nlm.nih.gov/pubmed/31228231
http://dx.doi.org/10.1002/pros.23843

Ejemplares similares